Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com ), a development-stage oncology and dermatology biopharmaceutical company, announces that Phase 2 final data on PV-10 for metastatic melanoma will be presented at the 2nd European PostASCO Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany.
Dr. Sanjiv Agarwala, M.D., Principal Investigator for the PV-10 Phase 2 trial, and Chief of Medical Oncology and Hematology at St. Luke's Hospital and Health Network in Bethlehem, PA, will be presenting the final Phase 2 PV-10 data at 9:24 a.m. (Munich time) that day.
Dr. Craig Dees, PhD, CEO of Provectus said, "This will be the first time that final Phase 2 data on PV-10 for metastatic melanoma will be publicly announced. Dr. Agarwala is expected to present a detailed analysis of PV-10's impact upon Progression Free Survival ("PFS"), which is also the suggested primary endpoint for the proposed Phase 3 clinical trial protocol to qualify for Special Protocol Assessment with the Food and Drug Administration (FDA). This conference is an important venue for Provectus as the data will be presented to members of the global scientific and medical community, including important leading investigators from Europe. The presentation of the final Phase 2 data will also be a significant milestone for the company as we continue in our path towards regulatory approval for our novel oncology drug."
Provectus Pharmaceuticals also expects PV-10 Phase 2 data will be featured in a peer-reviewed publication in upcoming months.
About the 2nd European PostASCO Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, http://melanomaglobal2012.org/
This conference is expected to attract interdisciplinary participants from all continents and offer a comprehensive overview on all new developments in melanoma therapy. The aim of this conference is to grant a deep overall insight into the development of new drugs for melanoma. The lively interaction of clinicians, as well as experts in translational and basic research, and representatives of the pharmaceutical industry, guarantees a successful outcome for every participant.
No comments:
Post a Comment